| Phase 12 trials |
|
Phase 1
|
NCT06961370 |
Jul 2025 → Jan 2027 expected |
age-related macular degeneration, diffuse secondary choroid atrophy |
Hoffmann-La Roche |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT00709527 |
Oct 2008 → Dec 2009 |
wet macular degeneration |
Ophthotech Corporation |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT03374670 |
Nov 2018 → Dec 2019 |
— |
Ophthotech Corporation |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT03364153 |
Jan 2018 → Mar 2025 |
Stargardt disease |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03362190 |
Oct 2017 → Oct 2018 |
wet macular degeneration |
Ophthotech Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05571267 |
Oct 2016 → Apr 2018 |
wet macular degeneration |
IVERIC bio, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02397954 |
Mar → Oct 2015 |
— |
Ophthotech Corporation |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT02686658 |
Dec 2015 → Sep 2019 |
diffuse secondary choroid atrophy, dry age related macular degeneration |
IVERIC bio, Inc. |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT05536297 |
Sep 2022 → Apr 2025 |
age-related macular degeneration, diffuse secondary choroid atrophy |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04435366 |
Jun 2020 → Jul 2022 |
age-related macular degeneration, diffuse secondary choroid atrophy |
IVERIC bio, Inc. |
Completed
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT06970665 |
Jul 2025 → Jun 2027 expected |
age-related macular degeneration, diffuse secondary choroid atrophy |
Astellas Pharma Inc |
Active not recruiting
|
No outcome recorded
|